{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:44:14Z","timestamp":1790858654524,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and objectives<\/jats:title><jats:p>Several recent clinical studies have indicated that vamorolone is comparable in effectiveness to glucocorticosteroids for treating Duchenne muscular dystrophy (DMD). However, there is a lack of extensive data regarding the efficacy and safety of various doses of vamorolone. We conducted a study to evaluate the efficacy of different doses of vamorolone in boys with DMD, and compare the safety of vamorolone vs. glucocorticosteroids, prednisone or deflazacort in boys with DMD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed systematic searches of the PubMed, Embase, and Cochrane Library databases for vamorolone, glucocorticosteroids, prednisone or deflazacort in boys with DMD. We assessed statistical heterogeneity across trials based on the Newcastle Ottawa scale (NOS) tool test and I<jats:sup>2<\/jats:sup> values, and mean differences were pooled using the random-effects model. We used traditional meta-analysis to evaluate efficacy and safety of vamorolone 6.0\u2009mg\/kg\/d vs. vamorolone 2.0\u2009mg\/kg\/d and vamorolone vs. prednisone. A network meta-analysis was applied to estimated the safety of vamorolone in comparison to glucocorticosteroids, prednisone and deflazacort. Our meta-analysis were performed using Revman 5.4 software, and our network meta-analysis were performed using Stata\/MP 18.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the meta-analysis, a total of 193 patients were analyzed across four clinical trials (97 patients receiving vamorolone 2\u2009mg\/kg per day; 96 patients receiving vamorolone 2\u2009mg\/kg per day). We observed that there were statistically significant differences in boys with DMD between vamorolone 6.0\u2009mg\/kg\/d and vamorolone 2.0\u2009mg\/kg\/d in TTSTANDV (MD\u2009=\u20090.03, 95%CI\u2009=\u20090.00\u20130.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), TTRWV (MD\u2009=\u20090.13, 95%CI\u2009=\u20090.08\u20130.19, <jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.01), 6MWT (MD\u2009=\u200924.54, 95%CI\u2009=\u20094.46\u201344.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), TTCLIMBV (MD\u2009=\u20090.04, 95%CI\u2009=\u20090.01\u20130.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.009), no significant difference in BMI z score (MD\u2009=\u20090.09, 95%CI\u2009=\u2009\u22120.03\u20130.20, <jats:italic>p<\/jats:italic>\u2009=\u20090.13). Indirect comparisons derived from network meta-analysis did not show significant differences among vamorolone, glucocorticosteroids, prednisone and deflazacort in BMI z score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings implied that boys with DMD who took vamorolone 6\u2009mg\/kg daily instead of 2\u2009mg\/kg daily may be safer and have superior motor function. However, more large sample randomized controlled trials are needed to confirm our results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>This systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration number: CRD42024562916).<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1456559","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:09:53Z","timestamp":1724346593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of different doses of vamorolone in boys with Duchenne muscular dystrophy: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Qin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linna","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"859930","DOI":"10.3389\/fmed.2022.859930","article-title":"Therapeutic strategies for dystrophin replacement in Duchenne muscular dystrophy","volume":"9","author":"Happi Mbakam","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","article-title":"Drug development progress in duchenne muscular dystrophy","volume":"13","author":"Deng","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neurol.2022.11.005","article-title":"Gene therapy review: Duchenne muscular dystrophy case study","volume":"179","author":"Berling","year":"2023","journal-title":"Rev Neurol (Paris)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/14737175.2023.2249607","article-title":"Gene therapy for Duchenne muscular dystrophy: an update on the latest clinical developments","volume":"23","author":"Happi Mbakam","year":"2023","journal-title":"Expert Rev Neurother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"175675","DOI":"10.1016\/j.ejphar.2023.175675","article-title":"Duchenne muscular dystrophy: current treatment and emerging exon skipping and gene therapy approach","volume":"947","author":"Patterson","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e208112","DOI":"10.1212\/wnl.0000000000208112","article-title":"Efficacy and safety of Vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e16267","DOI":"10.1111\/ene.16267","article-title":"Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids","volume":"31","author":"Schiava","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/wnl.0000000000012910","article-title":"Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data Meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e13172","DOI":"10.1111\/apha.13172","article-title":"Vamorolone treatment improves skeletal muscle outcome in a critical illness myopathy rat model","volume":"225","author":"Akkad","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/jcph.1632","article-title":"Exposure-response analysis of Vamorolone (VBP15) in boys with Duchenne muscular dystrophy","volume":"60","author":"Li","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e201800186","DOI":"10.26508\/lsa.201800186","article-title":"Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy","volume":"2","author":"Heier","year":"2019","journal-title":"Life Sci Alliance"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/wnl.0000000000008168","article-title":"Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function","volume":"93","author":"Hoffman","year":"2019","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of Vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref18","first-page":"96","article-title":"Efficacy and safety of vamorolone during 48-week treatment in patients with Duchenne muscular dystrophy (DMD) in VBP15-004 study","volume":"42","author":"Leinonen","year":"2023","journal-title":"Conf Abstr Acta Myol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/wnl.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejpn.2022.04.004","article-title":"Deflazacort dose optimization and safety evaluation in Duchenne muscular dystrophy (DOSE): a randomized, double-blind non-inferiority trial","volume":"38","author":"Reddy","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2217\/cer-2021-0018","article-title":"Meta-analyses of deflazacort versus prednisone\/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy","volume":"10","author":"Shieh","year":"2021","journal-title":"J Comp Eff Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::aid-mus4>3.0.co;2-f","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: a post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","article-title":"Developing standardized corticosteroid treatment for Duchenne muscular dystrophy","volume":"58","author":"Guglieri","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of Vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10571-014-0133-y","article-title":"VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis","volume":"35","author":"Dillingham","year":"2015","journal-title":"Cell Mol Neurobiol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2446","article-title":"Assessing Pharmacogenomic loci associated with the pharmacokinetics of Vamorolone in boys with Duchenne muscular dystrophy","author":"Li","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3233\/jnd-230161","article-title":"Considering the promise of Vamorolone for treating Duchenne muscular dystrophy","volume":"10","author":"Grounds","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1107474","DOI":"10.3389\/fneur.2023.1107474","article-title":"Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis","volume":"14","author":"Elhalag","year":"2023","journal-title":"Front Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/hmg\/ddad173","article-title":"Comparison of pharmaceutical properties and biological activities of prednisolone, deflazacort, and vamorolone in DMD disease models","volume":"33","author":"Liu","year":"2024","journal-title":"Hum Mol Genet"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1456559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:09:57Z","timestamp":1724346597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1456559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":35,"alternative-id":["10.3389\/fneur.2024.1456559"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1456559","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"article-number":"1456559"}}